Fujian Aonong Biological Technology Group Incorporation Stock Forum

Given the EBIT loss and extensive liabilities, Fujian Aonong Biological Technology's operational strategy is deemed high-risk. Only improved operations will make it an attractive investment. Their EBIT loss indicates no imminent profitability.

The company's lackluster revenue growth and absence of profits is concerning, despite a falling share price presenting a potential opportunity if long-term growth potential can be discerned.

Despite the strong growth forecast, the company's P/S is much lower than expected causing investors to question its ability to achieve the future growth expectations. Market participants seem to be pricing in certain risks leading to this lowered P/S ratio.